Hyperliquid Strategies (PURR) investor relations material

Executive summary

• Transitioned to a digital asset treasury model focused on accumulating and staking HYPE tokens, scaling holdings to 20 million tokens and maintaining $103 million in cash as of April 29, 2026.

• Completed disposition of legacy biotech/Sonnet assets, retaining a 40% equity stake in Guidant BioTherapeutics.

• Launched validator partnership with Unit Labs/Trade XYZ to generate recurring revenue and deepen ecosystem integration.

• Main business is accumulating and staking HYPE tokens to generate ongoing staking rewards.

• Expanded ecosystem participation and innovation with new market launches, including HIP-3 real world asset perps and outcome markets.

Financial highlights

• Net income for the quarter ended March 31, 2026, was $152.5 million, primarily from $198.4 million in unrealized gains on HYPE tokens.

• Nine-month net loss of $165.4 million, driven by a $169.2 million loss on HYPE contribution commitment, a $35.6 million IPR&D write-off, and a $60.5 million increase in deferred tax expense.

• Cash and cash equivalents as of March 31, 2026, were $113.1 million; HYPE digital assets valued at $689.0 million.

• Stockholders’ equity stood at $743.5 million as of March 31, 2026, with no debt.

• Generated $3.1 million in staking revenue and $1.9 million in interest income over nine months.

Outlook and guidance

• Focus remains on increasing per-share exposure to HYPE, expanding ecosystem participation, and launching new market initiatives such as HIP-3 RWA perps, portfolio margin, and outcome markets.

• Management expects existing resources to fund operations for at least 12 months and is evaluating further funding and cash deployment strategies.

• Anticipates continued growth from institutional adoption, Builder Codes, and ecosystem integration.